Tuberculosis may sound like a disease that belongs in a dusty history book beside powdered wigs and questionable medical leeches. Unfortunately, TB never received that memo. It remains a serious bacterial infection that usually affects the lungs but can also damage the brain, kidneys, spine, and other parts of the body.
So, is there a vaccine for tuberculosis? Yes. It is called the bacille Calmette-Guérin vaccine, better known as the BCG vaccine. It has been used for more than a century and is routinely given to infants in many countries where TB is common. However, it is rarely recommended in the United States because its protection varies, particularly against contagious pulmonary TB in adolescents and adults.
BCG is useful, but it is not an invisible force field. Understanding what the vaccine canand cannotdo helps explain why tuberculosis prevention still depends heavily on testing, early diagnosis, infection control, and treatment of inactive TB.
Evidence basis: Current CDC guidance and FDA-approved indication for BCG vaccination.
The Direct Answer: Yes, the BCG Vaccine Protects Against TB
BCG is currently the only licensed vaccine used to prevent tuberculosis in humans. It is made from a weakened form of Mycobacterium bovis, a close relative of Mycobacterium tuberculosis, the bacterium that causes TB in people.
The weakened organism does not normally cause tuberculosis in healthy vaccine recipients. Instead, it introduces the immune system to mycobacterial features so immune cells can respond more quickly if they later encounter TB bacteria. Think of it as giving the immune system a wanted poster rather than inviting the actual outlaw into town.
In countries with a high burden of TB, BCG is commonly administered shortly after birth. Its most important benefit is reducing the risk of severe childhood tuberculosis, including:
- TB meningitis, which affects the tissues surrounding the brain and spinal cord
- Miliary or disseminated TB, in which bacteria spread through the bloodstream
- Other life-threatening forms of tuberculosis in infants and young children
These protections matter because babies and young children have a greater risk of developing severe disease soon after infection. BCG can therefore be lifesaving even though it does not prevent every type of TB.
Evidence basis: CDC public and clinical vaccine guidance, historical CDC effectiveness review, and Mayo Clinic clinical overview.
How Effective Is the Tuberculosis Vaccine?
BCG works best against severe childhood TB
The strongest and most consistent evidence supports BCG vaccination for preventing TB meningitis and disseminated TB in children. That is why many national immunization programs prioritize vaccination during infancy rather than waiting until adulthood.
BCG protection can weaken over time, however, and its effectiveness against pulmonary tuberculosis varies considerably among populations. Pulmonary TB is especially important because a person with active disease in the lungs or throat can release bacteria into the air when coughing, speaking, or singing.
Protection against adult pulmonary TB is unpredictable
Studies of BCG have reported dramatically different results against adult lung disease. Geography, prior exposure to environmental mycobacteria, differences among vaccine strains, age at vaccination, genetics, nutrition, and other immune factors may all contribute to the variation.
In practical terms, a person who received BCG as a baby should not assume lifelong immunity. Vaccinated people can still become infected, develop active pulmonary TB, and transmit the bacteria to others. A BCG scar is evidence of a past vaccinationnot a permanent “TB-proof” badge.
The vaccine also does not cure inactive TB infection or active TB disease. Anyone exposed to TB still needs appropriate medical evaluation, regardless of vaccination history.
Evidence basis: CDC, NIH, NIAID, and Johns Hopkins explanations of BCG’s variable protection and the need for improved vaccines.
Why Is BCG Not Routinely Given in the United States?
It may seem strange that an available tuberculosis vaccine is not part of the standard U.S. childhood vaccine schedule. The decision is based on several practical considerations rather than a national dislike of four-letter abbreviations.
TB exposure is relatively uncommon for most U.S. residents
The average risk of encountering someone with infectious TB is lower in the United States than in countries where the disease is widespread. Public-health programs instead focus on identifying people at increased risk, testing them, treating inactive infection, and rapidly treating active disease.
Adult protection is too inconsistent for routine vaccination
Because BCG does not reliably prevent pulmonary TB in adults, universal vaccination would not eliminate the need for screening, exposure investigations, or preventive treatment. The vaccine would add another layer of protection in some situations, but it could not replace the rest of the TB-control toolbox.
BCG can complicate TB skin-test interpretation
BCG vaccination may cause a positive reaction to the tuberculin skin test. There is no dependable method for looking at a positive skin test and determining whether the reaction came from vaccination or true TB infection.
This does not mean every positive skin test in a vaccinated person is “just the vaccine.” Clinicians evaluate the result according to the person’s exposure history, medical risks, country of birth, symptoms, and other findings.
Evidence basis: CDC explanation of U.S. policy, testing limitations, and FDA labeling for high-risk individuals.
Who Might Receive BCG in the United States?
BCG vaccination is rarely indicated in the United States, but “rarely” does not mean “never.” Decisions should be made with a tuberculosis specialist and the appropriate state or local TB-control program.
According to CDC guidance, vaccination may be considered for a child who has a negative TB test but cannot be separated from an adult who has untreated or inadequately treated infectious TB. It may also be considered when the source patient has TB resistant to both isoniazid and rifampin and the child cannot receive effective preventive treatment.
In unusual occupational settings, BCG may be considered for health care workers when drug-resistant TB transmission is ongoing despite comprehensive infection-control measures. It is not a routine substitute for ventilation, respirators, isolation procedures, screening, or proper treatment.
Travel alone usually does not lead to BCG vaccination for an American adult. A short vacation is very different from prolonged, close exposure in a household, clinic, correctional facility, shelter, or other high-risk environment. Travelers with unusual exposure risks should discuss their plans with a clinician familiar with tuberculosis and travel medicine.
Evidence basis: Detailed CDC recommendations for children and health care workers.
How Are People Tested for TB After BCG Vaccination?
Two main types of tests can detect immune evidence of TB infection:
- The tuberculin skin test, sometimes called the Mantoux test or TST
- A TB blood test, also called an interferon-gamma release assay or IGRA
For people who have received BCG, a TB blood test is generally preferred. BCG does not cause a positive IGRA result because these tests use TB-specific proteins that are not present in the vaccine strains.
Available U.S. blood tests include QuantiFERON-TB Gold Plus and T-SPOT.TB. A blood sample is collected and analyzed to determine whether immune cells react to specific TB antigens.
A positive blood or skin test does not automatically mean a person has contagious TB. It means TB infection is possible and additional evaluation is necessary. That evaluation may include a symptom review, physical examination, chest imaging, and sputum testing.
If TB bacteria are present without symptoms or evidence of active disease, the diagnosis may be inactive or latent TB infection. Treating inactive TB can significantly reduce the chance that the bacteria will wake up later and cause active diseasebecause apparently TB bacteria are very patient and terrible houseguests.
Evidence basis: CDC IGRA, skin-testing and diagnostic guidance, plus Johns Hopkins testing guidance.
Is the BCG Vaccine Safe?
Most healthy recipients experience a local reaction at the injection site. Redness, swelling, a small sore, and eventual scarring may occur as the area heals. The familiar small upper-arm scar seen in many countries is commonly associated with childhood BCG vaccination.
More serious reactions are uncommon but can include significant lymph-node swelling, persistent injection-site problems, or infection caused by the vaccine organism. Because BCG is a live vaccine, people with weakened immune systems have a greater risk of serious complications.
CDC guidance states that BCG should not be given to people who are immunosuppressed, including those with HIV, or to people who are likely to become immunocompromised, such as some organ-transplant candidates. Pregnant women should not receive BCG because adequate safety evidence during pregnancy is lacking.
Individual health circumstances matter. A decision about BCG should come from a qualified clinician rather than a travel forum, a relative’s recollection, or a social-media account featuring a person in a lab coat of uncertain origin.
Evidence basis: CDC contraindication and safety recommendations.
Are Better TB Vaccines Being Developed?
Yes. Researchers are studying vaccines designed to prevent infection, stop inactive infection from progressing to active disease, strengthen BCG protection, or prevent recurrence after treatment.
One of the most advanced candidates is M72/AS01E, an investigational protein-based vaccine. In a Phase 2b trial involving adults with evidence of TB infection, it reduced progression to active pulmonary TB by approximately half over about three years of follow-up.
A large Phase 3 trial is now evaluating the candidate in adolescents and adults. As of June 2026, the trial had enrolled approximately 20,000 participants across five countries in Africa and Asia. The study is still ongoing, and no Phase 3 efficacy results are available yet. M72/AS01E therefore remains experimental and cannot currently be requested as a routine vaccine.
Other research approaches include modified live vaccines, protein-and-adjuvant vaccines, viral-vector platforms, mucosal vaccines, and mRNA technology. Scientists are also investigating whether changing the route of vaccination or improving immune-stimulating ingredients could produce stronger protection in the lungs.
TB vaccine development is unusually difficult because researchers still do not have a simple immune marker that guarantees protection. The bacteria can hide inside immune cells, remain inactive for years, and interact differently with each person’s immune system. TB is essentially playing hide-and-seek on expert mode.
Evidence basis: Phase 2b findings, ClinicalTrials.gov trial information, NIAID research programs, NIH-supported research, and the June 2026 Gates MRI update.
How Can Tuberculosis Be Prevented Without Routine Vaccination?
In the United States, TB prevention relies on targeted measures that can identify and interrupt infection before it spreads:
- Testing people with known exposure or increased risk
- Treating inactive TB infection before it becomes active
- Diagnosing active disease quickly
- Using multiple antibiotics exactly as prescribed
- Improving ventilation in high-risk indoor environments
- Using respiratory protection in appropriate health care settings
- Conducting public-health contact investigations
A person with suspected active pulmonary TB may need temporary isolation while testing and treatment begin. Once effective therapy has reduced infectiousness, normal activities can usually resume under medical guidance.
Anyone with a persistent cough, coughing up blood, unexplained weight loss, fever, night sweats, chest pain, or recent close TB exposure should seek medical care. Vaccination history should never be used as a reason to ignore symptoms.
Real-World Experiences With the TB Vaccine
The following examples are illustrative composite scenarios based on situations commonly encountered by families, travelers, students, workers, and clinicians. They are not descriptions of specific patients.
The immigrant student with a BCG scar
A university student who received BCG as a baby may be surprised when a U.S. school requests TB screening. The student points to the small scar on the upper arm and reasonably wonders, “Didn’t I already handle this?”
The answer is that vaccination and testing serve different purposes. BCG may have reduced the student’s risk of severe childhood TB, but it does not prove that infection never occurred later. Because the vaccine can affect a skin test, the clinic may order an IGRA blood test instead. If the blood test is negative and there are no major exposure risks or symptoms, no further evaluation may be needed. If it is positive, the clinician investigates for inactive or active TB rather than dismissing the result as a vaccination souvenir.
The parent moving between countries
A parent relocating with a newborn to a country where TB is common may encounter very different vaccine recommendations from those offered in the United States. Local physicians may recommend BCG soon after birth because infants face a meaningful risk of TB meningitis and disseminated disease.
The parent may initially feel confused: How can the same vaccine be routine in one country and unusual in another? The difference reflects local disease risk, not a contradiction in basic science. Seat belts are useful everywhere, but snow chains make more sense in Minnesota than Miami. Public-health recommendations change according to the hazard people are likely to encounter.
The health care worker with an old vaccination record
A nurse who received BCG overseas may worry that every employment screening will produce a positive TB skin test. In many workplaces, an IGRA simplifies the process because it is unaffected by BCG. The worker should keep previous test results, treatment records, and vaccination documentation whenever possible.
A positive result still deserves proper evaluation. Occupational health clinicians consider workplace exposure, previous residence, travel, immune status, symptoms, and chest imaging. An old BCG vaccination does not automatically explain away a new positive result, particularly after a documented exposure.
The traveler asking for a “just-in-case” TB shot
An adult planning a two-week trip may request BCG alongside routine travel vaccines. In most cases, a clinician will explain that BCG is not routinely recommended for short-term travelers from the United States. The discussion instead focuses on the nature and duration of exposure.
Staying in hotels and visiting outdoor attractions generally creates a different risk from working for months in a crowded clinic that treats infectious TB. Prevention may involve avoiding prolonged exposure in poorly ventilated spaces, following workplace respiratory precautions, and arranging testing after a significant exposure.
The household exposed to active TB
When a family member is diagnosed with contagious pulmonary TB, relatives sometimes ask whether they can quickly receive BCG and consider the matter settled. Unfortunately, BCG is not an emergency post-exposure treatment.
Household members need prompt testing and medical evaluation. Depending on age, immune status, test results, and the source patient’s drug-susceptibility pattern, preventive antibiotics may be recommended. Young children and immunocompromised contacts may require especially urgent assessment because they can progress from infection to serious disease more quickly.
These experiences share one lesson: BCG vaccination is only one part of tuberculosis prevention. Accurate records, risk-based testing, follow-up, and treatment remain essential. The vaccine may be the headline, but public-health work does most of the supporting acting.
Conclusion
There is a vaccine for tuberculosis: the BCG vaccine. It has protected generations of children from severe forms of TB and remains an important part of infant immunization programs in countries where exposure is common.
BCG is not routinely used in the United States because the average exposure risk is relatively low, protection against adult pulmonary TB is inconsistent, and vaccination can complicate skin-test interpretation. In rare high-risk situations, it may be considered with guidance from a TB expert and public-health authorities.
For people who previously received BCG, a TB blood test is generally preferred when screening is needed. Meanwhile, promising candidates such as M72/AS01E are being studied, but no newer vaccine has yet completed the approval process. Until that changes, testing, preventive treatment, early diagnosis, effective antibiotics, ventilation, and infection control remain the most dependable defenses against TB.
